Work

Data from Harnessing Immune Responses in the Tumor Microenvironment: All Signals Needed

Year: 2023

Type: other

Abstract: An agonist CD40 monoclonal antibody (CP-870,893), in combination with gemcitabine, is well tolerated in patients with advanced pancreatic adenocarcinoma. The combination results in induction of cytokines, B cell activation, and clinical responses. These findings support testing of immunotherapies in combination with other established and targeted therapies. Clin Cancer Res; 19(22); 6061–3. ©2013 AACR.

DOI: 10.1158/1078-0432.c.6522374.v1

Authors: Dung T. Le, Elizabeth M. Jaffee

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361958766

Cites:

Cited by:

Related to: 10